Funding profile · Women’s health devices

Ananya Health

A pre-regulatory cryoablation company whose documented capital is mostly federal. Two Form D filings cover $404,000 of SAFEs; three National Cancer Institute awards cover $2,694,507.

$2.69MNCI grant money on record, FY2022 to FY2025
$404KSold on the latest Form D, from 5 investors
87%Share of documented capital that is non-dilutive
$100KEHA Impact Ventures follow-on, September 2026, its third

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2020 Angel and friends and family Not disclosed Angels; $30,000 delivered and $35,000 committed as of a mid 2020 filing Company-stated
2021 Y Combinator, Summer 2021 Not disclosed Y Combinator YC data
Sep 2022 NCI SBIR Phase I, R43CA278186 $396,587 National Cancer Institute NIH
Early 2024 Existing investors, incl. eha Impact Ventures $250,000 eha Impact Ventures and existing holders; Evelyn Castle became board observer Company release
Sep 2024 to 2025 NCI SBIR Phase II, R44CA278186 $2,297,920 across two fiscal years National Cancer Institute NIH
From Mar 2025 SAFE offering, size reported as indefinite $200,000 at first filing, $404,000 by May 2026 2 investors, then 5 Form D
Jun 2025 BrightEdge strategic investment Not disclosed BrightEdge, the American Cancer Society venture fund; 2025 Entrepreneurs cohort of twelve Company release
Sep 2026 Follow-on $100,000 EHA Impact Ventures, third investment Independent reporting

What the filings show

Ananya Health, Inc. · Form D/A · filed May 15, 2026

First sale
Mar 27, 2025
Offered
Indefinite; securities described as SAFE
Sold
$404,000 · remaining indefinite
Investors
5 · average about $80,800
Exemption
Rule 506(b)
Related persons
Anu Parvatiyar (executive officer, director, CEO); Wei-Hsiang Chang (director)
Filing
SEC EDGAR, CIK 0002064779, Oakland CA, Delaware corporation

Ananya Health, Inc. · Form D · filed Apr 16, 2025

First sale
Mar 27, 2025
Offered
Indefinite; securities described as SAFE
Sold
$200,000
Investors
2 · average $100,000
Exemption
Rule 506(b)
Year of incorporation
2020
Filing
SEC EDGAR, CIK 0002064779, signed Apr 14, 2025

Reading the filings

  1. Most of the money is not equity.Federal awards total $2,694,507 against $404,000 of securities sold. Of the $3,098,507 documented, grants are 87%. For a device company six years old with no product on sale, that ratio is the story.
  2. One offering, two snapshots.Both filings carry the same first sale date of March 27, 2025. Over the thirteen months between them the amount sold rose from $200,000 to $404,000 and the investor count from two to five, so the three later cheques averaged about $68,000 against $100,000 for the first two. The amendment also flips the more than one year flag to true.
  3. No valuation has been disclosed.The offering total is reported as indefinite in both filings and the paper is SAFEs, which defer the price. Nothing on file establishes a post-money valuation, and no priced round appears anywhere in the record.
  4. Announced money that never reached a Form D.The September 2024 grant release describes an additional $250,000 from existing investors, five months before the offering’s first sale. The June 2025 BrightEdge investment and the September 2026 follow-on of $100,000 have no filing of their own as of this date. Issuers relying on Section 4(a)(2) rather than Regulation D file no Form D, so the gaps do not mean the money is imaginary.
  5. The first notice was late.First sale March 27, 2025; Form D signed April 14 and filed April 16, twenty days later, against the fifteen day window. A small company with no in-house counsel is the usual explanation.
  6. The board is two names.Anu Parvatiyar and Wei-Hsiang Chang appear as the only related persons on both filings. Chang is also the principal investigator on all three NCI awards. Evelyn Castle of eha Impact Ventures is described by the company as a board observer from early 2024 and does not appear on either filing, which is consistent with observer status.

Commercial signals

Signal Detail Source type
Regulatory No FDA 510(k) or PMA on record. The stated target is 510(k) clearance by mid-2027. Public record
Revenue Revenue range on both Form D filings: Decline to Disclose. No product is on sale. Public record
Availability Company website states that certain configurations are under development and not currently available in any geography. Company-stated
Partners Clinical organizations, advocacy groups and screening companies named for the United States, Mexico, Nigeria and India. Company-stated
Clinical evidence No registered trial and no peer-reviewed publication found for the device. Not found
Grant runway The Phase II project period ended August 31, 2026. No later award appears on record. Public record

What to watch

  • A Form D or amendment covering the September 2026 follow-on, due within 15 days of first sale if it was sold under Regulation D.
  • A priced round converting the SAFEs, which would put a valuation on the record for the first time.
  • A further NCI award or other non-dilutive funding, now that the Phase II period has ended.
  • A 510(k) submission, since the company and its investors have tied the next raise to that milestone.

The Ananya Health story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Cambridge Cancer Genomics: Shared investor: Company-Stated Partners. A Y Combinator backed British company that used repeat blood draws and machine learning to tell an oncologist when a cancer drug had stopped working
  • Flint: Shared investor: Company-Stated Partners. Flint recruits nurses and other clinicians from overseas, and from asylum, TPS and DACA pools already inside the United States, and places them as direct, permanent
  • Pirouette Pharma: Shared investor: Company-Stated Partners. A disk-shaped, push-button auto-injector built by three engineers who met running a student rocket lab, now paired with old drugs on abbreviated FDA pathways
  • Macromoltek: Shared investor: Company-Stated Partners. An Austin software company that has designed antibodies inside a computer since 2011, paid for by federal grants and customer fees rather than venture rounds

Sources

  1. Public recordForm D, Ananya Health, Inc., CIK 0002064779SEC · Apr 16, 2025
  2. Public recordForm D/A, Ananya Health, Inc., CIK 0002064779SEC · May 15, 2026
  3. Public recordNIH RePORTER R43CA278186 and R44CA278186NCI · FY2022 to FY2025
  4. Public record510(k) and PMA databases, searched for Ananya Health and CRCLFDA · Sep 22, 2026
  5. IndependentEIV invests $100,000 in Ananya Health for cervical cancer deviceThe Nation · Sep 8, 2026
  6. IndependentFirm invests $100,000 in cervical cancer prevention devicePunch Healthwise · Sep 9, 2026
  7. InterviewEmpowering Innovation in Women’s Health, NCI SBIR Innovation Lab, episode 23National Cancer Institute · Nov 8, 2024
  8. CompanyAnanya Health secures $2.3M SBIR grant from the National Cancer InstituteAnanya Health · Sep 3, 2024
  9. CompanyAnanya Health receives strategic investment from BrightEdgeAnanya Health · Jun 23, 2025
  10. CompanySolution overview and funding disclosuresMIT Solve · 2020
  11. PartnerEHA Impact Ventures portfolio and approacheha.ventures · accessed Sep 22, 2026

Compiled from SEC, NIH and FDA public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Ananya Health. This page is not an offer to sell or a recommendation to buy any security.